Verily, Samsung Collaborate, Improving AI Trustworthiness, FDA Approval for PathAI
By Bio-IT World Staff
March 24, 2026 | Verily Life Sciences and Samsung Electronics America announce a collaboration; Research Solutions launches Scite MCP; PathAI announces Breakthrough Device Designation to PathAssist Derm; and more.
Verily Life Sciences and Samsung Electronics America announced a collaboration that will bring together Samsung’s Galaxy Watch 8 with Verily’s precision health platform, Pre, to provide an integrated solution for generating evidence and monitoring real-world populations. Through this collaboration, Verily will fully integrate sensor data from the Samsung Galaxy Watch and make it accessible in its Viewpoint Evidence solution, which is built on the Verily Pre platform and enables research sponsors to run real-world studies with re-contactable participant cohorts. The partnership aims to accelerate research for life sciences and government customers by combining advanced health analytics with consumer-grade wearable data. Press release.
Research Solutions announced the launch of Scite MCP, which enables researchers and developers to search scientific literature and evaluate the trustworthiness of research findings without leaving the AI tools they already use. While large language models can generate fluent text on most topics, their coverage of scholarly material is limited, and they struggle to distinguish well-supported findings from contested ones. Scite MCP solves this by giving AI tools direct access to over 250 million indexed articles, book chapters, preprints, and datasets, along with Scite's proprietary Smart Citations. The Scite MCP connects to ChatGPT, Claude, Microsoft Copilot, Cursor, Claude Code, and any AI tool that supports the Model Context Protocol standard. Key capabilities include answers grounded in trustworthy research, citation context, broad literature coverage, and works across tools. Press release.
Veristat expanded regulatory and clinical trial services to international pharmaceutical and medical device companies seeking a streamlined path into European, including the U.K. and Switzerland, plus Australian, Canadian, and U.S. markets. Particularly, Veristat has helped many Chinese companies — including Hansoh Pharma and CStone Pharmaceuticals — successfully navigate regional regulatory requirements and legal complexities leading to product approvals. Veristat is currently expanding to provide comprehensive regional clinical trial support. Press release.
PathAI announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation to PathAssist Derm, designed to analyze digital pathology whole slide images of skin lesions and aid pathologists in their review. By leveraging advanced AI technology to support case assessment and workflow prioritization, PathAssist Derm is designed to help pathologists manage rising caseloads while maintaining diagnostic rigor. Press release.
Illumina and Nashville Biosciences announced two advancements in scale and depth of the Alliance for Genomic Discovery. With the addition of Regeneron Genetics Center (RGC) as the tenth member, the Alliance can expand the core dataset to 312,000 whole genomes. The Alliance also announced a new initiative: a dataset of 50,000 additional whole genomes with paired proteomic data generated using Illumina Protein Prep. GSK is among the first participants in this multiomic expansion. Press release.
Illumina also entered a strategic partnership with SPT Labtech to develop a novel automated sample preparation platform designed to streamline and standardize genomics workflows across decentralized healthcare environments. The collaboration will focus on helping labs support improved patient care in oncology by enabling broader access to high-quality genomic characterization of disease. By bringing advanced automation to laboratories of all sizes and settings, the collaboration also aims to accelerate the delivery of actionable insights from sample to result. Press release.
Insilico Medicine launched PandaClaw, a transformative new feature of the PandaOmics engine that combines AI agents with biological and bioinformatics workflows. By automating complex real-time analyses, the tool enables researchers to seamlessly discover novel targets, identify new indications, and build disease hypotheses through an intuitive, intelligent natural language interface, thereby accelerating translational medical research. Press release.
Insilico also entered a partnership with Liquid AI that creates lightweight scientific foundation models for pharmaceutical research. The collaboration has produced LFM2-2.6B-MMAI (v0.2.1), a single checkpoint trained to perform at state-of-the-art levels across multiple drug discovery subdomains, not a patchwork of separate point models. The partnership tackles a critical challenge facing pharmaceutical companies today: how to harness AI capabilities without sending proprietary molecules, assays, and target data to external cloud services. By combining Liquid AI's efficient LFM architecture with Insilico's MMAI Gym, (a comprehensive training platform with over 1,000 pharmaceutical benchmarks), the work shows that on-premises deployment can deliver competitive results across the full spectrum of drug discovery tasks in a single system. Press release.
Cytiva and the San Raffaele Telethon Institute for Gene Therapy (SR TIGET), launched a new collaboration to advance next generation genomic medicine platforms. The initiative aims to help researchers and developers address some of the most persistent bottlenecks in cell and gene therapy, targeting high-impact areas where even small gains can meaningfully help move from discovery to delivery faster. The collaboration will combine the scientific leadership of SR-TIGET with Cytiva’s manufacturing expertise, spanning process development through commercialization, with additional partnership from two other Danaher companies, Aldevron and Integrated DNA Technologies. Press release.
Dalriada and Topos announced a research collaboration to accelerate experimental validation for IDP drug discovery using advanced protein mass spectrometry and proteomics. Under the collaboration, Topos will leverage Dalriada's expertise and infrastructure in protein mass spectrometry and chemoproteomics to support discovery efforts against intrinsically disordered and conformationally dynamic targets, protein classes that often lack stable structure and are difficult to interrogate with conventional structure-based approaches. Press release.
Sartorius launched the modular Eveo Cell Therapy Platform, an integrated system for the production and quality control of autologous cell therapies. The platform is designed to address structural manufacturing bottlenecks that limit scalability and patient access to transformative treatments such as CAR-T therapies. With its latest innovation, Sartorius introduces a fundamentally new approach to cell therapy production that strengthens the company's position in the dynamic advanced therapies market. Sartorius has collaborated with ElevateBio and other partners to test out the Eveo platform. Press release.
Abselion has established a U.S. subsidiary at The Engine in Cambridge, Massachusetts. The new location strengthens its presence in the North American life sciences ecosystem and provides a formal base to support more direct engagement with academic, biotech, and pharma research teams working across biologics characterization and development workflows. The U.S. site will offer Abselion with an organizational framework to complement its established collaborations and support its next stage of development as interest in its Amperia protein quantification system extends beyond the U.K. and Europe. Press release.
Nicoya Lifesciences launched FastHDX, a new hydrogen-deuterium exchange mass spectrometry platform. FastHDX is the first platform engineered to measure protein structural dynamics and conformational changes at millisecond resolution, enabling direct interrogation of transient states that are inaccessible with conventional techniques. Key benefits of the platform include broad labeling time range, millisecond labeling resolution, low sample consumption, and more. Press release.
Panome Bio announced the launch of MassID, a cloud-based computational platform designed to dramatically improve how researchers process and interpret untargeted LC/MS metabolomics data. MassID was developed to solve the challenge of limitations caused by the complexity of LC/MS datasets. The platform provides an end-to-end computational pipeline that converts raw LC/MS/MS data into cleaned, normalized, and annotated metabolite profiles while also introducing probability-based confidence scoring for the metabolite identifications made. Press release.
Nautilus Biotechnology debuted the Voyager Platform, which is designed to power the Iterative Mapping of up to 10 billion intact proteins and proteoforms simultaneously in a single run. The platform can identify and quantify intact protein molecules with machine-learning powered analysis — all on an integrated platform with a user-friendly touchscreen interface and benchtop design that requires no special lab facility requirements. The Voyager Platform is the result of Nautilus’ unique cross-disciplinary approach to protein analysis, combining integrated reagents, fluidics, imaging, ultra-dense nano-array flow cells, and machine learning-powered algorithms, to enable Iterative Mapping and deliver on the full potential of proteomics. Press release.